TP53 and cancer: Several strategies to reactivate mutant p53 in cancer are being explored, including small-molecule stabilizers of the thermolabile mutant Y220C [13, 14], metallochaperones for zinc-binding deficient mutants [12, 15], and cysteine-binding compounds APR-246/MQ, 2-sulfonylpyrimidines, and arsenic trioxide that target a wider range of p53 mutants [16–19].